This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ acipimox,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Lipid-lowering Effects: Acipimox belongs to a class of medications known as nicotinic acid derivatives or niacin analogs. It exerts its lipid-lowering effects primarily by inhibiting the release of free fatty acids (FFAs) from adipose tissue, which leads to a decrease in triglyceride synthesis and secretion by the liver.

  2. Reduction of Triglycerides: Acipimox effectively lowers plasma triglyceride levels, particularly in individuals with elevated fasting triglyceride concentrations. It helps reduce the production of triglyceride-rich lipoproteins (e.g., very low-density lipoprotein or VLDL) and decreases circulating levels of triglycerides.

  3. Increase in HDL Cholesterol: In addition to lowering triglycerides, acipimox may modestly increase high-density lipoprotein (HDL) cholesterol levels. HDL cholesterol is often referred to as "good" cholesterol because it helps remove excess cholesterol from the bloodstream and transport it to the liver for excretion.

  4. Improvement of Lipid Profile: Acipimox may lead to favorable changes in the lipid profile, including reductions in total cholesterol, LDL cholesterol (low-density lipoprotein), and triglycerides, as well as increases in HDL cholesterol. These changes contribute to a more balanced and healthier lipid profile.

  5. Management of Dyslipidemia: Acipimox is used as an adjunctive therapy in the management of dyslipidemia, particularly in patients with hypertriglyceridemia who have not achieved adequate lipid control with lifestyle modifications (e.g., diet, exercise) alone or with other lipid-lowering medications such as statins.

  6. Anti-diabetic Effects: Acipimox may also have beneficial effects on glucose metabolism and insulin sensitivity, particularly in individuals with type 2 diabetes mellitus and associated dyslipidemia. By reducing circulating FFAs and triglycerides, acipimox helps improve insulin sensitivity and glycemic control.

  7. Dosage and Administration: Acipimox is typically administered orally in the form of tablets. The dosage and frequency of administration may vary depending on the patient's lipid profile, response to treatment, and tolerability. It is usually taken with meals to minimize gastrointestinal side effects.

  8. Side Effects: Common side effects of acipimox may include flushing, pruritus (itching), gastrointestinal symptoms (e.g., nausea, abdominal discomfort), and transient elevations in liver enzymes. Flushing is the most common adverse effect and is often dose-dependent. Taking acipimox with food or using sustained-release formulations may help reduce flushing.

  9. Contraindications: Acipimox is contraindicated in individuals with active peptic ulcer disease, severe hepatic dysfunction, or hypersensitivity to the drug or its components. It should be used with caution in patients with renal impairment or pre-existing liver disease, and liver function tests should be monitored periodically during treatment.

  10. Drug Interactions: Acipimox may interact with other medications, particularly those metabolized by cytochrome P450 enzymes or affecting lipid metabolism. Concurrent use with other lipid-lowering agents (e.g., statins) or antidiabetic medications may require dosage adjustments or close monitoring for potential adverse effects or interactions.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of acipimox,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by acipimox,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Veillonella genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Ruminococcus genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Lacticaseibacillus genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Agathobacter genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Phocaeicola genus Decreases 👪 Source Study
Escherichia coli O1:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O139:H1 no rank Decreases 👶 Source Study
Escherichia coli O141:H4 no rank Decreases 👶 Source Study
Escherichia coli O145:H34 no rank Decreases 👶 Source Study
Escherichia coli O15:H12 no rank Decreases 👶 Source Study
Escherichia coli O155:H21 no rank Decreases 👶 Source Study
Escherichia coli O158:H23 no rank Decreases 👶 Source Study
Escherichia coli O16:H48 no rank Decreases 👶 Source Study
Escherichia coli O170:H18 no rank Decreases 👶 Source Study
Escherichia coli O18ac:H14 no rank Decreases 👶 Source Study
Escherichia coli O19:H7 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H4 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H5 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O20:H12 no rank Decreases 👶 Source Study
Escherichia coli O25:H16 no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O68:H12 no rank Decreases 👶 Source Study
Escherichia coli O7:H15 no rank Decreases 👶 Source Study
Escherichia coli O78:H51 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O84:H7 no rank Decreases 👶 Source Study
Escherichia coli O85:H1 no rank Decreases 👶 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens B no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Clostridium perfringens E no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Escherichia coli O121 serogroup Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O155 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O177 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O3 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O78 serogroup Decreases 👶 Source Study
Escherichia coli O86 serogroup Decreases 👶 Source Study
Escherichia coli O91 serogroup Decreases 👶 Source Study
Escherichia coli H20 serotype Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O1:HNT serotype Decreases 👶 Source Study
Escherichia coli O10:H32 serotype Decreases 👶 Source Study
Escherichia coli O100:H21 serotype Decreases 👶 Source Study
Escherichia coli O103:H2 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O111:H- serotype Decreases 👶 Source Study
Escherichia coli O111:H8 serotype Decreases 👶 Source Study
Escherichia coli O111:NM serotype Decreases 👶 Source Study
Escherichia coli O112ab:H8 serotype Decreases 👶 Source Study
Escherichia coli O112ac:H19 serotype Decreases 👶 Source Study
Escherichia coli O113:H21 serotype Decreases 👶 Source Study
Escherichia coli O114:H49 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O125ac:K+:H10 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O128ac:H12 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:H25 serotype Decreases 👶 Source Study
Escherichia coli O145:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O15:H18 serotype Decreases 👶 Source Study
Escherichia coli O150:H6 serotype Decreases 👶 Source Study
Escherichia coli O152:H23 serotype Decreases 👶 Source Study
Escherichia coli O157:H- serotype Decreases 👶 Source Study
Escherichia coli O157:H43 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O16:H6 serotype Decreases 👶 Source Study
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O174:H21 serotype Decreases 👶 Source Study
Escherichia coli O176:H45 serotype Decreases 👶 Source Study
Escherichia coli O2:H6 serotype Decreases 👶 Source Study
Escherichia coli O2:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:H1 serotype Decreases 👶 Source Study
Escherichia coli O25:NM serotype Decreases 👶 Source Study
Escherichia coli O26:H11 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O45:H2 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:H4 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Escherichia coli O8:H8 serotype Decreases 👶 Source Study
Escherichia coli O89m:H10 serotype Decreases 👶 Source Study
Escherichia coli O89m:H9 serotype Decreases 👶 Source Study
Escherichia coli O9:H10 serotype Decreases 👶 Source Study
Escherichia coli O99:H6 serotype Decreases 👶 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Clostridioides difficile species Decreases 📓 Source Study Colitis
Bifidobacterium adolescentis species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Dorea formicigenerans species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Ruminococcus bromii species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Mediterraneibacter gnavus species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study High Levels linked to long-lived individuals
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Roseburia intestinalis species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Candidatus Akkermansia intestinavium species Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study

Impact of acipimox,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.2 -0.2
ADHD 1.7 0 0
Age-Related Macular Degeneration and Glaucoma 0.2 0 0
Allergic Rhinitis (Hay Fever) 0.7 0.9 -0.29
Allergies 3.6 1 2.6
Allergy to milk products 1.1 0.6 0.83
Alopecia (Hair Loss) 0.9 0.9
Alzheimer's disease 1.7 3.1 -0.82
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.6 0.9 0.78
Ankylosing spondylitis 2.9 0.5 4.8
Anorexia Nervosa 0 1.1 0
Antiphospholipid syndrome (APS) 1 1
Asthma 0.3 0.3 0
Atherosclerosis 0.8 0.7 0.14
Atrial fibrillation 1.7 0.7 1.43
Autism 4.3 3.8 0.13
Barrett esophagus cancer 0.5 0.2 1.5
benign prostatic hyperplasia 0.4 0.4
Biofilm 1.3 1.3
Bipolar Disorder 0.6 0.7 -0.17
Brain Trauma 0.6 0.2 2
Cancer (General) 0.2 1.3 -5.5
Carcinoma 2.1 1.5 0.4
Celiac Disease 1.7 1.7 0
Cerebral Palsy 0.9 0.7 0.29
Chronic Fatigue Syndrome 3.2 2.4 0.33
Chronic Kidney Disease 1.3 0.8 0.63
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 1 0.3 2.33
Chronic Urticaria (Hives) 1.9 0.3 5.33
Coagulation / Micro clot triggering bacteria 1.4 0.8 0.75
Colorectal Cancer 2.3 0.6 2.83
Constipation 0.7 0.5 0.4
Coronary artery disease 0.6 0.8 -0.33
COVID-19 6.2 5.3 0.17
Crohn's Disease 3.9 2.6 0.5
cystic fibrosis 1.2 0.4 2
deep vein thrombosis 1.2 0.4 2
Depression 3.9 3.6 0.08
Dermatomyositis 0.2 0.2 0
Eczema 0.9 0.7 0.29
Endometriosis 2.2 0.9 1.44
Eosinophilic Esophagitis 0.1 0.4 -3
Epilepsy 2 0.8 1.5
Fibromyalgia 0.9 0.4 1.25
Functional constipation / chronic idiopathic constipation 2.5 1.7 0.47
gallstone disease (gsd) 1.5 0.4 2.75
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 1 -0.43
Generalized anxiety disorder 1.7 0.4 3.25
giant cell arteritis 0.1 -0.1
Glioblastoma 0.2 -0.2
Graves' disease 0.7 1.1 -0.57
Halitosis 0.6 0.2 2
Hashimoto's thyroiditis 1.6 0.3 4.33
Hidradenitis Suppurativa 0.2 0.4 -1
High Histamine/low DAO 1.2 0.3 3
hypercholesterolemia (High Cholesterol) 0.3 0.1 2
hyperglycemia 0.4 0.8 -1
Hyperlipidemia (High Blood Fats) 0.6 0.4 0.5
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 1.4 2.7 -0.93
Hypothyroidism 0.6 -0.6
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 1.1 -1.1
Inflammatory Bowel Disease 2.5 2.6 -0.04
Insomnia 0.7 0.4 0.75
Intelligence 0.1 0.1
Intracranial aneurysms 0.6 0.4 0.5
Irritable Bowel Syndrome 2.6 1.5 0.73
Liver Cirrhosis 2.4 1.3 0.85
Long COVID 3.4 4.9 -0.44
Low bone mineral density 0.3 -0.3
Lung Cancer 0.7 0.6 0.17
Mast Cell Issues / mastitis 0.6 0.3 1
ME/CFS with IBS 0.4 1.3 -2.25
ME/CFS without IBS 0.4 0.6 -0.5
Menopause 1 1
Metabolic Syndrome 4.6 3.1 0.48
Mood Disorders 5.5 3.6 0.53
multiple chemical sensitivity [MCS] 0.6 0.4 0.5
Multiple Sclerosis 1.5 1.5 0
Multiple system atrophy (MSA) 1 0.7 0.43
neuropathic pain 0.9 -0.9
Neuropathy (all types) 0.6 0.4 0.5
neuropsychiatric disorders (PANDAS, PANS) 1 1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.6 2.8 -0.75
NonCeliac Gluten Sensitivity 1.1 0.3 2.67
Obesity 5.1 1.7 2
obsessive-compulsive disorder 4.4 1.8 1.44
Osteoarthritis 1 0.1 9
Osteoporosis 1.1 0.6 0.83
pancreatic cancer 0.4 0.4
Parkinson's Disease 4.2 2.9 0.45
Polycystic ovary syndrome 1.1 0.8 0.38
Postural orthostatic tachycardia syndrome 0.1 0.2 -1
Premenstrual dysphoric disorder 1 0 0
primary biliary cholangitis 0.1 0.4 -3
Psoriasis 3.4 0.3 10.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.3 1.9 0.74
Rosacea 0.9 0.2 3.5
Schizophrenia 3.1 0.9 2.44
scoliosis 0.5 -0.5
Sjögren syndrome 2.4 1.5 0.6
Sleep Apnea 0.7 0.7 0
Slow gastric motility / Gastroparesis 1.4 0.2 6
Small Intestinal Bacterial Overgrowth (SIBO) 1 0 0
Stress / posttraumatic stress disorder 1.5 0.9 0.67
Systemic Lupus Erythematosus 2.1 1.2 0.75
Tic Disorder 0.3 0.7 -1.33
Tourette syndrome 0 0.1 0
Type 1 Diabetes 2 1.3 0.54
Type 2 Diabetes 4.5 2.5 0.8
Ulcerative colitis 2.3 1.1 1.09
Unhealthy Ageing 2.8 0.6 3.67
Vitiligo 0.9 0.3 2

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]